Sometimes depression doesn’t lift, even after trying multiple treatments. For some people, symptoms persist despite therapy, medication, and sustained effort.

Treatment Resisitent Depression

We’re intentional about the kind of company we’re building. Our values guide how we work, how we make decisions, and how we advance science toward better options for depression.

Our values

EvoDenovo is a biotechnology company dedicated to accelerating patient access to evidence-based innovations for depression.

Our research

New generation antidepressant Biologics

EvoDenovo is advancing a precision biologics platform for depression and other CNS disorders, centered on engineered single-domain antibodies. By combining selectivity, modular engineering, and a development strategy built for speed and discipline, we aim to generate therapies that are both scientifically differentiated and operationally executable. The result is a biologic approach designed to translate compelling neuroscience into practical, scalable treatment options for patients who remain poorly served by current care.

Gemini_Generated_Image_yfefgzyfefgzyfef (1)

thecuriousid_young_modern_indonesian_man_looking_happy_and_calm_e33980c5-0598-4b39-b52f-7a1439373356

mGlyR and Depression

EvoDenovo’s science centers on mGlyR, recently identified as a metabotropic glycine receptor (mGlyR): glycine binds an extracellular Cache domain and modulates a noncanonical signaling axis built around the RGS7–Gβ5 complex, with downstream effects on cAMP and cortical neuronal excitability. In the prefrontal cortex, mGlyR is reported to be upregulated in major depressive disorder, and in mice chronic stress increases mGlyR in a glucocorticoid-dependent manner; overexpression induces depressive-like behavior, while loss of mGlyR produces an antidepressant-like phenotype and stress resilience.

For brain disorders like depression, nanobodies offer a new way to drug hard targets. Their selectivity enables clean modulation of biology that small molecules often struggle to reach, opening the door to first-in-class approaches

Against Depression

Nanobodies

Precision Biologics

Nanobodies

Mission

Our mission is to put patients first by developing transformative antidepressant therapies that work rapidly and lastingly, built through rigorous translational science and a development path designed for broad clinical impact.

Collaborators

seattle-children-s-university-of-washington-children-s-hospital-pediatrics-hospital-children-thumbnail-1

We use rigorous science to reimagine mental health treatment.

EvoDenovo is a biotechnology company dedicated to accelerating patient access to evidence-based innovations for depression.

2026

Targeting mGlyR with nanobodies for depression

2021

Cryo-EM structure of human GPR158 receptor coupled to the RGS7-Gβ5 signaling complex

2023

Orphan receptor GPR158 serves as a metabotropic glycine receptor: mGlyR

2018

Orphan receptor GPR158 controls stress-induced depression

Restoring Network Plasticity

Management Team

Ira Kalfus

Clinical Development Strategist

30+ years in medicine and 15+ years in drug development, with a track record including FDA approvals and successful acquisitions.

Sid Labed

Founder & CEO

Sid Labed is a serial biotech founder and Harvard Medical School alum

Anas Fathallah

Translational & Clinical pharmacologist

former Biogen Senior Translational/Clinical Pharmacologist Leader, overseeing preclinical development at EvoDenovo.

Founders